CD44 and ovarian cancer: Indeed, we previously showed that the CD44+/MyD88+ EOC stem cells are able to undergo epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) [39], which are processes that are indispensable in the generation of metastatic disease - a major contributor to ovarian cancer mortality.